FDA approves first Barth Syndrome treatment, Forzinity
Biospace - 21-Sep-2025Stealth BioTherapeutics wins accelerated FDA approval for its mitochondrial therapy elamipretide
Join the club for FREE to access the whole archive and other member benefits.
Seasoned journalist and senior editor at BioSpace
Heather McKenzie is a seasoned journalist and senior editor at BioSpace with over five years of focused experience covering the biopharmaceutical sector, especially in areas like neuroscience and gene therapy. Prior to her role in biotechnology journalism, she spent eight years producing high-level business content for conferences across sectors such as pharma/biotech, legal, energy, and corporate strategy. Originally from Toronto and having lived in Chicago and Chesapeake, Virginia, she brings a broad geographic and professional perspective to her writing. Outside of work she enjoys creative writing, family time, and caring for her energetic Russian Blue cat Roofus.
Visit website: https://www.biospace.com/heather-mckenzie
See alsoDetails last updated 22-Oct-2025
Stealth BioTherapeutics wins accelerated FDA approval for its mitochondrial therapy elamipretide